Email Updates

You are here

AVAC in the News

  • As the world waits with baited breath for a safe and effective vaccine to prevent SARS-CoV-2, the new coronavirus that causes COVID-19, people living with HIV are concerned that they may be excluded from clinical trials testing these vaccines.

    July 30, 2020
  • A vaginal ring that has been undergoing trials has been given approval by the European Medicines Agency to be used as an HIV prevention method among women who have tested negative.

    July 25, 2020
    The Independent
  • In 1984, scientists discovered the virus at the root of an alarming epidemic that was sickening otherwise healthy young men with aggressive cancers and rare, life-threatening pneumonias. Thirty-six years later, there still is no HIV vaccine. But instead of being a cautionary tale of scientific hubris, that unsuccessful effort is leading to even greater confidence in the search for a coronavirus vaccine, from some of the same researchers who have spent their careers seeking a cure for AIDS.

    July 14, 2020
    HIV Vaccine, General
    Washington Post
  • The conversation at AIDS 2020 is focusing not just on developing new technologies to fight HIV/AIDS — but also ensuring the tools that already exist realize their potential for impact. As the world falls short of 2020 targets for progress on HIV/AIDS, global health experts are highlighting the need to make testing, prevention, and treatment affordable and accessible.

    July 8, 2020
  • An injection every two months is three times more effective in preventing HIV infection among men and transgender women than a daily prevention pill.

    July 8, 2020
  • Even in the days of the internet, conferences remain the lifeblood of science. Young thrusters can meet old fogeys and lobby them for jobs. Ideas can be swapped in the knowledge that no electronic trail will come back to haunt you. And journalists can swoop, scoop up a bundle of interesting stories and, with luck, provide an update to their readers and viewers of developments in whatever field the conference was about.

    July 8, 2020
    The Economist
  • Researchers discussed HIV prevention research during a press conference at the AIDS 2020 meeting, highlighting the importance of involving young people and women. The event included perspectives from various researchers on successful interventions and disruptions to treatment because of the COVID-19 pandemic.

    July 8, 2020
  • Back in March, Quadeer Jones, a 23-year-old actor in Los Angeles, decided to get pre-exposure prophylaxis, or PrEP, to protect himself from HIV when having sex. He made an appointment at the Los Angeles LGBT Center to get PrEP medication, the antiretroviral Truvada, traveling more than 30 miles. Once he arrived at the center, the process was relatively easy. “I had to schedule an appointment for rapid HIV testing,” he says. “They said I was negative. I got my prescription and meds and I was out the door in about an hour.”

    July 7, 2020
    Capital & Main
  • Taken every 2 months, the long-acting injectable drug cabotegravir (CAB-LA) prevented more HIV infections than daily oral pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC), according to newly announced results from a major Phase 3 study. The results were released originally in May due to the overwhelmingly positive data on CAB-LA for PrEP, but researchers presented their final data in early July at the 23rd International AIDS Conference (AIDS 2020).

    July 7, 2020
    The BodyPro
  • New clinical evidence shows that cabotegravir, an investigative injectable drug under development for HIV prevention and treatment, is 66 percent more effective than oral preexposure prophylaxis.

    July 7, 2020